DOX-TPP is primarily utilized in the field of targeted drug delivery, especially in cancer therapy. It combines the chemotherapeutic agent doxorubicin (DOX) with a mitochondrial-targeting ligand, triphenylphosphonium (TPP), to enhance the precision of drug delivery. This conjugate is designed to specifically target cancer cell mitochondria, where it can induce apoptosis more effectively. By concentrating the drug within the mitochondria, DOX-TPP minimizes damage to healthy cells, reducing side effects commonly associated with traditional chemotherapy. Its application is particularly promising in treating resistant cancers, as it overcomes some of the limitations of conventional treatments by improving cellular uptake and therapeutic efficacy.